Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclin B1 peptide-pulsed autologous dendritic cell vaccine
- Development stage
- Phase 1
- Lead developer
- University of Pittsburgh
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous
01
Overview
Cyclin B1 peptide-pulsed autologous dendritic cell vaccine is an investigational immunotherapy designed to elicit a cytotoxic T-lymphocyte (CTL) response against tumor cells that overexpress cyclin B1. Cyclin B1 (CCNB1) is a regulatory protein essential for the G2/M phase transition of the cell cycle; while it is expressed at low levels in normal cells, it is significantly overexpressed in various malignancies, including non-small cell lung cancer (NSCLC), breast cancer, and colorectal cancer. The vaccine is produced by harvesting a patient's own peripheral blood mononuclear cells via leukapheresis, differentiating them into dendritic cells (DCs) in vitro, and pulsing them with MHC-restricted cyclin B1 peptides. These antigen-loaded dendritic cells are then re-administered to the patient, where they function as professional antigen-presenting cells to prime and expand cyclin B1-specific T-cells, potentially leading to the targeted destruction of cancer cells.
- Other names
- cyclin B1-pulsed autologous dendritic cell vaccinecyclin B1-pulsed DC vaccinecyclin B1-pulsed dendritic cell vaccine
02
Targets
CCNB1 (Cyclin B1)
Beyond the preview
Go deeper on cyclin B1 peptide-pulsed autologous dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclin B1 peptide-pulsed autologous dendritic cell vaccine.